In a statement, Genentech noted that the price of drugs to treat multiple sclerosis had risen sharply in recent years. An estimated 400,000 people have multiple sclerosis in the United States, and about 15 percent have the primary progressive form of the disease. While they normally help the body fight off infections, they are believed to malfunction and contribute to central nervous system damage in people with multiple sclerosis. Advertisement Continue reading the main story“I think if the safety holds up, it will become the leading M.S. The clinical trial showed a slightly heightened rate of tumors in patients with primary progressive multiple sclerosis, which he said needed to be monitored closely.

Source: New York Times March 29, 2017 02:15 UTC